156 related articles for article (PubMed ID: 38784592)
1. Characterizing health-related quality of life and identifying disease predictors among patients suspected of having long COVID: an analysis of COMET-ICE clinical trial data.
Gelhorn HL; Ghafoori P; Cutts K; Birch H; Savva Y; Satram S; Lloyd E; Chen WH
Front Public Health; 2024; 12():1278106. PubMed ID: 38784592
[TBL] [Abstract][Full Text] [Related]
2. Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.
Satram S; Ghafoori P; Reyes CM; Keeley TJH; Birch HJ; Brintziki D; Aldinger M; Alexander E; Lopuski A; Sarkis EH; Gupta A; Shapiro AE; Powers JH
J Patient Rep Outcomes; 2023 Sep; 7(1):92. PubMed ID: 37702920
[TBL] [Abstract][Full Text] [Related]
3. Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron.
Di Fusco M; Sun X; Moran MM; Coetzer H; Zamparo JM; Alvarez MB; Puzniak L; Tabak YP; Cappelleri JC
J Patient Rep Outcomes; 2023 Jul; 7(1):77. PubMed ID: 37486567
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus
Keeley TJH; Satram S; Ghafoori P; Reyes C; Birch HJ; Raymond K; Gelhorn HL; Kosinski M; Saucier CD; Mitchell Foster A; Lopuski A; Powers JH
Qual Life Res; 2023 Jun; 32(6):1645-1657. PubMed ID: 36703019
[TBL] [Abstract][Full Text] [Related]
6. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
7. Factor Analysis in Distinguishing Coronavirus Disease 2019 From Other Influenza-like Illness Using a Validated Patient-Reported Outcome Instrument FLU-PRO Plus: A Prospective Real-world Cohort Study.
Chrenka EA; Roblin DW; Gander JC; Powers JH; Cromwell LX; Kodthala PX; Whiting TS; Sesay MM; Segall MF; Deneal AN; Truitt AR; Sour EU; Martinson BC
Med Care; 2023 May; 61(5):288-294. PubMed ID: 36917774
[TBL] [Abstract][Full Text] [Related]
8. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
[TBL] [Abstract][Full Text] [Related]
9. Impaired health-related quality of life in long-COVID syndrome after mild to moderate COVID-19.
Malesevic S; Sievi NA; Baumgartner P; Roser K; Sommer G; Schmidt D; Vallelian F; Jelcic I; Clarenbach CF; Kohler M
Sci Rep; 2023 May; 13(1):7717. PubMed ID: 37173355
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Long-COVID-19 and its Impact on Quality of Life: Longitudinal Analysis at 3, 6 and 9 Months after Discharge from a Portuguese Centre.
Gaspar P; Dias M; Parreira I; Gonçalves HD; Parlato F; Maione V; Atalaia Barbacena H; Carreiro C; Duarte L
Acta Med Port; 2023 Oct; 36(10):647-660. PubMed ID: 36827994
[TBL] [Abstract][Full Text] [Related]
11. Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients.
Di Fusco M; Sun X; Moran MM; Coetzer H; Zamparo JM; Puzniak L; Alvarez MB; Tabak YP; Cappelleri JC
J Patient Rep Outcomes; 2022 Dec; 6(1):123. PubMed ID: 36469198
[TBL] [Abstract][Full Text] [Related]
12. Systematic surveillance of patient-reported symptoms of viral respiratory tract infectious Syndromes in diverse populations.
Gander JC; Chrenka E; Cromwell L; Truitt AR; Sesay M; Segall M; Amouzou SA; Hudgins AF; Kodthala P; Roblin D; Deneal AN; Whiting T; Powers JH; Martinson BC
BMC Health Serv Res; 2022 Dec; 22(1):1591. PubMed ID: 36581932
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
14. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study.
Huang L; Li X; Gu X; Zhang H; Ren L; Guo L; Liu M; Wang Y; Cui D; Wang Y; Zhang X; Shang L; Zhong J; Wang X; Wang J; Cao B
Lancet Respir Med; 2022 Sep; 10(9):863-876. PubMed ID: 35568052
[TBL] [Abstract][Full Text] [Related]
15. Health-Related Quality of Life for Patients with Post-Acute COVID-19 Syndrome: Identification of Symptom Clusters and Predictors of Long-Term Outcomes.
Lapin B; Li Y; Englund K; Katzan IL
J Gen Intern Med; 2024 Jun; 39(8):1301-1309. PubMed ID: 38424349
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal course and predictors of health-related quality of life, mental health, and fatigue, in non-hospitalized individuals with or without post COVID-19 syndrome.
Kirchberger I; Meisinger C; Warm TD; Hyhlik-Dürr A; Linseisen J; Goßlau Y
Health Qual Life Outcomes; 2024 Apr; 22(1):32. PubMed ID: 38616282
[TBL] [Abstract][Full Text] [Related]
17. Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression.
Lokhandwala T; Acharya M; Farrelly E; Coutinho AD; Bell CF; Svedsater H
J Manag Care Spec Pharm; 2022 Nov; 28(11):1261-1271. PubMed ID: 36282931
[No Abstract] [Full Text] [Related]
18. COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health.
Richard SA; Epsi NJ; Lindholm DA; Malloy AMW; Maves RC; Berjohn CM; Lalani T; Smith AG; Mody RM; Ganesan A; Huprikar N; Colombo RE; Colombo CJ; Madar C; Jones MU; Larson DT; Ewers EC; Bazan S; Fries AC; Maldonado CJ; Simons MP; Rozman JS; Andronescu L; Mende K; Tribble DR; Agan BK; Burgess TH; Pollett SD; Powers JH;
Open Forum Infect Dis; 2022 Jul; 9(7):ofac275. PubMed ID: 35873301
[TBL] [Abstract][Full Text] [Related]
19. Assessing the impact of COVID-19 at 1-year using the SF-12 questionnaire: Data from the Anticipate longitudinal cohort study.
O'Kelly B; Vidal L; Avramovic G; Broughan J; Connolly SP; Cotter AG; Cullen W; Glaspy S; McHugh T; Woo J; Lambert JS
Int J Infect Dis; 2022 May; 118():236-243. PubMed ID: 35301101
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
